Sanmamed and team demonstrated that combinatorial treatment with urelumab and nivolumab (anti-human PD-1 antibody) enhances CD8+ T cell-mediated anti-tumor responses in xenograft models of human colon and gastric carcinoma 56. Here, PDCD1 is linked to neoplasm.